Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
fda
2
×
life sciences
national blog main
national top stories
abbvie
alkermes
allergan
boston
buprenorphine
cancer
cancer immunotherapy
cariprazine
center for medicare and medicaid services
clinical trials
companion diagnostic
daniel o'day
deals
eli lilly
europe
europe blog main
europe top stories
felipe jain
foundation medicine
foundationone cdx
foundationone heme
genentech
jess fiedorowicz
jessica jeffrey
karim calis
lumateperone
m health fairview
marc goodman
massachusetts general hospital
national institutes of health (nih)
new york blog main
olanzapine
opioid
What
gain
2
×
medicine
vote
2
×
acquire
agreed
alkermes
antipsychotic
benefits
big
billion
broad
caveats
commonly
confidence
designed
didn’t
drug
effect
favor
fda
foundation
genentech
momentum
morning
offer
panel
panels
pay
pays
picked
prescribed
profiling
psyche
recently
redux
remaining
rest
roche
share
stock
Language
unset
Current search:
gain
×
fda
×
vote
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine